Literature DB >> 10384197

The prognosis of surgically resected N2 non-small cell lung cancer: the importance of clinical N status.

K Suzuki1, K Nagai, J Yoshida, M Nishimura, K Takahashi, Y Nishiwaki.   

Abstract

BACKGROUND: Clinical trials dealing with multimodal strategy for N2 non-small cell lung cancer are now being watched with keen interest, and the feasibility of this strategy is to be confirmed. N2 lung cancer, however, is composed of several subgroups with different prognoses. The prognostic factors still remain controversial.
METHODS: Between January 1986 and July 1997, 222 patients with lung cancer underwent surgical intervention at our institute; these patients were eventually given a diagnosis of metastasis to ipsilateral mediastinal lymph nodes. All patients underwent mediastinal lymph node dissection or sampling. Sixteen clinicopathologic factors were investigated by univariable and multivariable analyses to identify significant prognostic factors among resected N2 disease. Clinical N status was evaluated by computed tomographic scan.
RESULTS: The overall 5-year survival was 27%. Multivariable analyses among overall patients revealed 4 significant prognostic factors (P <.05): clinical N2 status, incomplete resection, larger tumor size, and multiple diseased N2 nodes. Based on the result, 32 patients with both clinical N2 status and pathologic multiple N2 nodes showed a 5-year survival of 5%, whereas 76 patients with neither of the factors showed a 5-year survival of 57% (P <.001).
CONCLUSION: The prognosis of surgically resected N2 disease varies tremendously according to the 4 significant prognostic factors. These factors should be clearly described in reporting clinical trials on N2 lung cancer. Clinical N status evaluated by computed tomographic scan should be 1 criterion to perform a clinical trial for N2 disease among a homogeneous population with respect to prognosis.

Entities:  

Mesh:

Year:  1999        PMID: 10384197     DOI: 10.1016/S0022-5223(99)70153-4

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  19 in total

1.  Prognostic Factors for Surgically Resected N2 Non-small Cell Lung Cancer.

Authors:  Keishi Kawasaki; Yasunori Sato; Yoshio Suzuki; Haruhisa Saito; Yukihiro Nomura; Yukihiro Yoshida
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-01-26       Impact factor: 1.520

2.  Prognostic significance of preoperative serum carcinoembryonic antigen in non-small cell lung cancer: a meta-analysis.

Authors:  Xiao-Bin Wang; Jie Li; Yi Han
Journal:  Tumour Biol       Date:  2014-07-15

3.  Which subgroup of patients with pathologic N2 non-small cell lung cancer benefit from surgery?

Authors:  Yasunobu Funakoshi; Yukiyasu Takeuchi; Hidenori Kusumoto; Toru Kimura; Hajime Maeda
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-25       Impact factor: 4.553

4.  Differential expression of VASP in normal lung tissue and lung adenocarcinomas.

Authors:  L Dertsiz; G Ozbilim; Y Kayisli; G A Gokhan; A Demircan; U A Kayisli
Journal:  Thorax       Date:  2005-07       Impact factor: 9.139

5.  Postoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: a retrospective study of 221 cases from a single institution.

Authors:  Honghai Dai; Zhouguang Hui; Wei Ji; Jun Liang; Jima Lu; Guangfei Ou; Zongmei Zhou; Qinfu Feng; Zefen Xiao; Dongfu Chen; Hongxing Zhang; Weibo Yin; Jie He; Luhua Wang
Journal:  Oncologist       Date:  2011-04-11

6.  Association between clinicopathological factors and postoperative radiotherapy in patients with completely resected pathological N2 non-small cell lung cancer.

Authors:  Yujin Xu; Jianqiang Li; Jin Wang; Xiao Hu; Honglian Ma; Pu Li; Xiao Zheng; Ming Chen
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

7.  Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables.

Authors:  Thierry Berghmans; Marianne Paesmans; Jean-Paul Sculier
Journal:  Ther Adv Med Oncol       Date:  2011-05       Impact factor: 8.168

Review 8.  Controversies regarding T status and N status for non-small cell lung cancer.

Authors:  Yanli Mo; Jiayin Peng; Wenmei Su; Xinggui Chen; Aibing Wu; Jinmei Li; Zhixiong Yang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

9.  Economic analysis of combined endoscopic and endobronchial ultrasound in the evaluation of patients with suspected non-small cell lung cancer.

Authors:  Gavin C Harewood; Jorge Pascual; Massimo Raimondo; Timothy Woodward; Margaret Johnson; Barbara McComb; John Odell; Laith H Jamil; Kanwar Rupinder S Gill; Michael B Wallace
Journal:  Lung Cancer       Date:  2009-05-26       Impact factor: 5.705

10.  Results of video-assisted thoracic surgery versus thoracotomy in surgical resection of pN2 non-small cell lung cancer in a Chinese high-volume Center.

Authors:  Chengwu Liu; Chenglin Guo; Fanyi Gan; Jiandong Mei; Qiang Pu; Zheng Liu; Yunke Zhu; Hu Liao; Lin Ma; Feng Lin; Lunxu Liu
Journal:  Surg Endosc       Date:  2020-05-11       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.